



To all concerned

October 27, 2016
Company:FINDEX Inc.
Representative:President & CEO
Teruo Aibara
(Securities code:3649)
Contact:Director and Head of Administration
Atsushi Fujita
(TEL:+81-89-947-3388)

Notification of a Revision to the Performance Forecast

We are revising our performance forecast for the Fiscal Year 2016, which we have published in the Financial Highlights for Fiscal Year 2015 (Japanese accounting standards, unconsolidated) on February 12, 2016 as follows:

Note

1. Revision to the performance forecasts for the Fiscal Year 2016 (January 1, 2016–December 31, 2016)

| | Sales | Operating income | Ordinary income | Net income | Earnings per share |
|--|-------------|------------------|-----------------|-------------|--------------------|
| | million yen | million yen | million yen | million yen | yen |
| Previous forecast (A) | 4,050 | 1,200 | 1,200 | 800 | 31.02 |
| Revised forecast (B) | 3,240 | 675 | 675 | 450 | 17.49 |
| Changes (B - A) | △810 | △525 | △525 | △350 | — |
| Percentage changes (%) | △20.0 | △43.8 | △43.8 | △43.8 | — |
| (Reference) Actual results of the previous fiscal year (FY 2015) | 2,951 | 670 | 671 | 441 | 17.00 |

2. Reasons for the revision to the performance forecast

With regard to sales in the non-radiation section in the medical field for FY 2016, there were changes in some cases projected for the fourth quarter, such as a change in the timing of system implementation in accordance with the rebuilding of a medical institution and the postponement due to budget allotment and other circumstances at a hospital. As a result, of the initial sales forecast, 473 million yen was carried over to the next fiscal period. Additionally, we and some other companies were unable to win a package deal of 176 million yen with other systems including other company's electronic medical record system. However, most of the factors above do not cause any concerns for the our business in and after the next fiscal period. Our products continue to be highly regarded by medical institutions.

Sales in the radiation field are expected to fall below the initial forecast by 155 million yen due to the change in the market environment including a longer system replacement cycle. Concerning agents, sales and the number of new agents acquired have steadily increased.

In the non-medical field, we concentrated on establishing a model case even though selling prices remain low during the current fiscal year, which has resulted in certain accomplishments. We consider that our efforts in this field will greatly contribute to sales in and after the next fiscal period.

There are no items of special mention concerning profits as expenses are under control within the budget. Due to a decrease in sales, however, profits are expected to fall below the performance forecast.

Due to the situation above, we have revised the performance forecast as indicated in the table above while both sales and profits are expected to slightly exceed the results of the previous fiscal year.

The performance forecast has been prepared based on information available as of the date of this release, and the actual performance may differ from the forecast.